Home › Companies › ACLARIS THERAPEUTICS INC. › 2024-2025
At ACLARIS THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 78 asset managers reported how they voted in their SEC Form N-PX filings, covering 375 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — ACLARIS THERAPEUTICS INC.'s filing reports the proposal as approved, with 77% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ACLARIS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 5, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2025: 7 items on ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 5, 2025: 4 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ACLARIS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ACLARIS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Neal Walker | 71,892,109 | -- | -- | 796,191 | 10,173,211 | 99% | Not verified | — |
| Elect Director: Andrew Schiff, M.D. | 71,700,813 | -- | -- | 987,487 | 10,173,211 | 99% | Not verified | — |
| Elect Director: William Humphries | 56,697,844 | -- | -- | 15,990,456 | 10,173,211 | 78% | Not verified | — |
| 2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement | 55,498,271 | 16,981,505 | 208,524 | -- | 10,173,211 | 77% | Approved | — |
| 3. The Certificate of Amendment | 79,590,285 | 3,035,422 | 235,804 | -- | -- | 96% | Approved | — |
| 4. The 2025 Plan | 56,963,260 | 15,536,097 | 188,943 | -- | 10,173,211 | 79% | Approved | — |
| 5. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 | 82,516,266 | 328,439 | 16,806 | -- | -- | 99.6% | Approved | — |
Source: ACLARIS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 5, 2025 — read the filing on EDGAR.
Each item below shows how the 78 asset managers that disclosed a ACLARIS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ACLARIS THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Andrew Schiff
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Andrew Schiff, M.D.”): 71,700,813 for, 987,487 withheld, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 7,109,123 for, 51,136 withheld, 10,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 430,319 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 78,782 | 0 | 0 | 0 | For |
| BlackRock | 60,428 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 43,917 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 41,579 | Withhold |
| Invesco | 37,303 | 0 | 0 | 0 | For |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Goldman Sachs | 31,878 | 0 | 0 | 0 | For |
| T. Rowe Price | 26,200 | 0 | 0 | 0 | For |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 12,500 | 0 | 0 | 0 | For |
| Equitable | 12,418 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 0 | 6,720 | Withhold |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 2,837 | Withhold |
| John Hancock | 2,262 | 0 | 0 | 0 | For |
| Allianz | 0 | 0 | 2,030 | 0 | Abstain |
| State Street | 654 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 430 | 0 | 0 | 0 | For |
| Victory Capital | 98 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Neal Walker
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal Walker”): 71,892,109 for, 796,191 withheld, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 7,108,693 for, 51,566 withheld, 10,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 430,319 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 78,782 | 0 | 0 | 0 | For |
| BlackRock | 60,428 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 43,917 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 41,579 | Withhold |
| Invesco | 37,303 | 0 | 0 | 0 | For |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Goldman Sachs | 31,878 | 0 | 0 | 0 | For |
| T. Rowe Price | 26,200 | 0 | 0 | 0 | For |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 12,500 | 0 | 0 | 0 | For |
| Equitable | 12,418 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 0 | 6,720 | Withhold |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 2,837 | Withhold |
| John Hancock | 2,262 | 0 | 0 | 0 | For |
| Allianz | 0 | 0 | 2,030 | 0 | Abstain |
| State Street | 654 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 430 | Withhold |
| Victory Capital | 98 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: William Humphries
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: William Humphries”): 56,697,844 for, 15,990,456 withheld, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 6,372,364 for, 725,205 withheld, 73,601 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 430,319 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 78,782 | Withhold |
| BlackRock | 0 | 0 | 60,428 | 0 | Abstain |
| FORUM FUNDS II | 0 | 0 | 0 | 43,917 | Withhold |
| Dimensional | 0 | 0 | 0 | 41,579 | Withhold |
| Invesco | 0 | 0 | 0 | 37,303 | Withhold |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 31,878 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 26,200 | Withhold |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 12,500 | Withhold |
| Equitable | 0 | 0 | 0 | 12,418 | Withhold |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 0 | 6,720 | Withhold |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 2,837 | Withhold |
| John Hancock | 0 | 0 | 2,262 | 0 | Abstain |
| Allianz | 0 | 0 | 2,030 | 0 | Abstain |
| State Street | 0 | 0 | 0 | 654 | Withhold |
| Advisors' Inner Circle Fund III | 430 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 98 | Withhold |
100% of fund votes cast · no official result
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares.
The 14 asset managers below reported 7,012,906 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 430,319 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 78,782 | 0 | 0 | 0 | For |
| Dimensional | 41,579 | 0 | 0 | 0 | For |
| Invesco | 37,303 | 0 | 0 | 0 | For |
| Goldman Sachs | 31,878 | 0 | 0 | 0 | For |
| T. Rowe Price | 26,200 | 0 | 0 | 0 | For |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 12,500 | 0 | 0 | 0 | For |
| Equitable | 12,418 | 0 | 0 | 0 | For |
| Prudential/PGIM | 6,720 | 0 | 0 | 0 | For |
| State Street | 654 | 0 | 0 | 0 | For |
| Victory Capital | 98 | 0 | 0 | 0 | For |
97% of fund votes cast · no official result
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 200,000,000 SHARES TO 400,000,000 SHARES.
The 8 asset managers below reported 111,080 for, 3,267 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 60,428 | 0 | 0 | 0 | For |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Jackson National | 8,881 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 2,837 | 0 | 0 | Against |
| John Hancock | 2,262 | 0 | 0 | 0 | For |
| Allianz | 2,030 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 430 | 0 | 0 | Against |
91% of fund votes cast · no official result
Description as filed by funds: TO APPROVE THE ACLARIS THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN.
The 24 asset managers below reported 6,517,228 for, 610,039 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 430,319 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 78,782 | 0 | 0 | Against |
| BlackRock | 60,428 | 0 | 0 | 0 | For |
| Dimensional | 0 | 41,579 | 0 | 0 | Against |
| Invesco | 37,303 | 0 | 0 | 0 | For |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Goldman Sachs | 31,878 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 26,200 | 0 | 0 | Against |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 12,500 | 0 | 0 | Against |
| Equitable | 12,418 | 0 | 0 | 0 | For |
| Jackson National | 0 | 8,881 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 6,720 | 0 | 0 | Against |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 2,837 | 0 | 0 | 0 | For |
| John Hancock | 0 | 2,262 | 0 | 0 | Against |
| Allianz | 0 | 2,030 | 0 | 0 | Against |
| State Street | 0 | 654 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 430 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 98 | 0 | 0 | Against |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 0 | 14 | 0 | 0 | Against |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Combines 5 wordings of this item as funds reported it.
77% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card.
ACLARIS THERAPEUTICS INC.’s own tally for this item (“2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 55,498,271 for, 16,981,505 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 430,319 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 78,782 | 0 | 0 | Against |
| BlackRock | 0 | 60,428 | 0 | 0 | Against |
| FORUM FUNDS II | 0 | 43,917 | 0 | 0 | Against |
| Dimensional | 0 | 41,579 | 0 | 0 | Against |
| Invesco | 0 | 37,303 | 0 | 0 | Against |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 31,878 | 0 | 0 | Against |
| T. Rowe Price | 0 | 26,200 | 0 | 0 | Against |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 12,500 | 0 | 0 | Against |
| Equitable | 0 | 12,418 | 0 | 0 | Against |
| Jackson National | 0 | 8,881 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 6,720 | 0 | 0 | Against |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 2,837 | 0 | Abstain |
| John Hancock | 0 | 2,262 | 0 | 0 | Against |
| Allianz | 0 | 2,030 | 0 | 0 | Against |
| State Street | 654 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 430 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 98 | 0 | 0 | Against |
Fund voting reports, all 23 managers: 6,373,018 for, 795,315 against, 2,837 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9,627,304 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 8,888,888 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 0 | 5,046,309 | 0 | 0 | Against |
| Decheng Capital LLC | 0 | 0 | 0 | 0 | -- |
| DE Shaw | 0 | 2,390,971 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 2,057,694 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 1,346,855 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,132,984 | 0 | 0 | 0 | For |
| BlackRock | 21,953 | 1,048,148 | 0 | 0 | Against |
| Aldebaran Capital, LLC | 1,010,880 | 0 | 0 | 0 | For |
| Citadel | 979,454 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 501,075 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 443,319 | 0 | 0 | Against |
| Fidelity | 440,617 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 434,455 | 0 | 0 | 0 | For |
| State Street | 393,727 | 13,798 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 0 | 331,600 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 297,093 | 0 | 0 | Against |
| Northern Trust | 0 | 268,277 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 247,121 | 0 | 0 | Against |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0 | 195,421 | 0 | 0 | Against |
| Renaissance | 0 | 176,182 | 0 | 0 | Against |
| T. Rowe Price | 0 | 149,300 | 0 | 0 | Against |
| Graham Capital Management, L.P. | 0 | 145,532 | 0 | 0 | Against |
| Dimensional | 0 | 114,109 | 0 | 0 | Against |
Institutional-manager reports, all 65 managers: 25,829,610 for, 12,534,080 against, 4,041,736 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.6% Approved · of votes cast
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2025.
ACLARIS THERAPEUTICS INC.’s own tally for this item (“5. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025”): 82,516,266 for, 328,439 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 5: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 7,168,333 for, 2,837 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,952,857 | 0 | 0 | 0 | For |
| Fidelity | 1,358,019 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 430,319 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 78,782 | 0 | 0 | 0 | For |
| BlackRock | 60,428 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 43,917 | 0 | 0 | 0 | For |
| Dimensional | 41,579 | 0 | 0 | 0 | For |
| Invesco | 37,303 | 0 | 0 | 0 | For |
| Charles Schwab | 33,079 | 0 | 0 | 0 | For |
| Goldman Sachs | 31,878 | 0 | 0 | 0 | For |
| T. Rowe Price | 26,200 | 0 | 0 | 0 | For |
| Pacific Life | 23,579 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 12,500 | 0 | 0 | 0 | For |
| Equitable | 12,418 | 0 | 0 | 0 | For |
| Jackson National | 8,881 | 0 | 0 | 0 | For |
| Prudential/PGIM | 6,720 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 2,837 | 0 | Abstain |
| John Hancock | 2,262 | 0 | 0 | 0 | For |
| Allianz | 2,030 | 0 | 0 | 0 | For |
| State Street | 654 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 430 | 0 | 0 | 0 | For |
| Victory Capital | 98 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 108,281,239 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.57% |
| 2 | Fidelity | 1.25% |
| 3 | BRIDGEWAY FUNDS INC | 0.40% |
| 4 | ALPS ETF Trust | 0.07% |
| 5 | BlackRock | 0.06% |
| 6 | FORUM FUNDS II | 0.04% |
| 7 | Dimensional | 0.04% |
| 8 | Invesco | 0.03% |
| 9 | Charles Schwab | 0.03% |
| 10 | Goldman Sachs | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.89% |
| 2 | Vivo Capital, LLC | 8.21% |
| 3 | Rock Springs Capital Management LP | 4.66% |
| 4 | Decheng Capital LLC | 3.73% |
| 5 | DE Shaw | 2.21% |
| 6 | MARSHALL WACE, LLP | 1.90% |
| 7 | Two Sigma | 1.24% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.05% |
| 9 | BlackRock | 0.99% |
| 10 | Aldebaran Capital, LLC | 0.93% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BML Investment Partners, L.P. | 12.88% | 13G |
| Biosion, Inc. | 10.42% | 13G |
| Deep Track Capital, LP | 8.63% | 13G |
| RA Capital Management, L.P. | 7.04% | 13G |
| Vivo Opportunity Fund Holdings, L.P. | 5.51% | 13G |
| Adage Capital Management, L.P. | 4.87% | 13G |
| Rock Springs Capital Management LP | 4.66% | 13G |
| Vanguard Group | 4.59% | 13F |
| Millennium Management | 3.82% | 13F |
| D.E. Shaw | 2.72% | 13F |
Percentages above are of 108,281,239 shares outstanding, as reported by ACLARIS THERAPEUTICS INC. on its Form 10-Q dated April 30, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACLARIS THERAPEUTICS INC.’s 10-Q dated April 30, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ACLARIS THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “ACLARIS THERAPEUTICS (ACRS) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aclaris-therapeutics-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.